Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
Myeloproliferative neoplasms: a contemporary review
A Tefferi, A Pardanani - JAMA oncology, 2015 - jamanetwork.com
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)
constitute theBCR-ABL1–negative myeloproliferative neoplasms and are characterized by …
constitute theBCR-ABL1–negative myeloproliferative neoplasms and are characterized by …
[HTML][HTML] Classification and personalized prognosis in myeloproliferative neoplasms
J Grinfeld, J Nangalia, EJ Baxter… - … England Journal of …, 2018 - Mass Medical Soc
Background Myeloproliferative neoplasms, such as polycythemia vera, essential
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …
[HTML][HTML] Somatic mutations of calreticulin in myeloproliferative neoplasms
T Klampfl, H Gisslinger, AS Harutyunyan… - … England Journal of …, 2013 - Mass Medical Soc
Background Approximately 50 to 60% of patients with essential thrombocythemia or primary
myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to …
myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to …
Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
A Tefferi, P Guglielmelli, TL Lasho… - British journal of …, 2020 - Wiley Online Library
Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is
currently based on clinically‐derived variables; we examined the possibility of integrating …
currently based on clinically‐derived variables; we examined the possibility of integrating …
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Under the auspices of an International Working Group, seven centers submitted diagnostic
and follow-up information on 1545 patients with World Health Organization-defined …
and follow-up information on 1545 patients with World Health Organization-defined …
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
E Rumi, D Pietra, V Ferretti, T Klampfl… - Blood, The Journal …, 2014 - ashpublications.org
Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a
calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential …
calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential …
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
A Tefferi, TL Lasho, P Guglielmelli, CM Finke… - Blood …, 2016 - ashpublications.org
Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by
JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; …
JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; …
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management
Abstract Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …
myeloproliferative neoplasms respectively characterized by erythrocytosis and …
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management
Disease overview Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and …
myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and …